<DOC>
	<DOCNO>NCT02953704</DOCNO>
	<brief_summary>The purpose prospective , longitudinal , noninterventional study describe clinical characteristic , evolution disease burden , treatment pattern patient select subcategories essential thrombocythemia ( ET ) myelofibrosis ( MF ) .</brief_summary>
	<brief_title>Myelofibrosis Essential Thrombocythemia Observational Study ( MOST )</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>MF cohort : Diagnosis MF lowrisk use DIPSS risk categorization OR intermediate1 risk DIPSS reason age alone . ET cohort : Diagnosis ET age ≥ 60 year OR history thromboembolic event OR currently receive ETdirected therapy ( eg , hydroxyurea , anagrelide , interferon , busulfan , ruxolitinib , etc ) . Willing able provide write informed consent . Willing able complete patient assessment questionnaires either alone minimal assistance caregiver and/or train site personnel . Under supervision physician current care MF ET . Individuals participate blind investigational drug study . Individuals participate Incyte investigational/interventional drug trial ( company investigatorsponsored study ) complete 30day end study visit . Life expectancy ≤ 6 month . Diagnosis secondary acute myeloid leukemia , myelodysplastic syndrome , chronic myelogenous leukemia , secondary thrombocytosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>clinical characteristic</keyword>
	<keyword>disease burden</keyword>
	<keyword>patient-reported outcome</keyword>
</DOC>